Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The global respiratory inhalers market was valued at USD 33.5 billion in 2023, with the Middle East and Africa holding a significant market share. The market is driven by the rising burden of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, with the values likely to attain USD 53.9 billion by 2032.
Respiratory inhalers are used to administer medication directly into the lungs to treat respiratory conditions. These devices contain different types of medications such as bronchodilators (to relax the muscles in the airways), corticosteroids (to reduce inflammation), and combination therapies (containing both bronchodilators and corticosteroids). There is a growing shift towards the development of combination inhaler therapies which consists of multiple medications in a single inhaler device, driving the demand for combination inhalers (aerosol or dry powder inhalers). Further, the rising advancements in digital inhaler technologies such as smart inhalers are expected to significantly contribute to the Middle East and Africa respiratory inhalers market growth.
The market is influenced by rising burden of respiratory conditions that directly impact the demand for effective respiratory inhalers. Recent data reveals that the prevalence of asthma is relatively high in the United Arab Emirates, accounting for 10-15% of the adult population and 20-25% of school-aged children. Similarly, it is estimated that over 10-15% of adults and 20% of children in South Africa are affected by asthma along with a high number of deaths caused by the condition. This increasing prevalence of respiratory diseases, attributed to factors such as smoking, air pollution, and changing lifestyle patterns, is anticipated to fuel the Middle East and Africa respiratory inhalers market demand in the coming years.
One of the major market trends include an increasing focus on the development of eco-friendly inhaler technologies in the region. For instance, in April 2024 , Mundipharma (a global healthcare company with a strong presence in the Middle East and Africa) in collaboration with contract development and manufacturing organization (CDMO) Vectura announced plans to reformulate an established flutiform® pressurized metered-dose inhaler (pMDI) for asthma treatment. The remodelling aims at reducing the product’s carbon footprint by incorporating an environment friendly propellant. The growing efforts toward the advancement of respiratory inhaler technology with a lower environmental impact is projected to elevate the market value.
The report offers a detailed analysis of the market based on the following segments:
Market Breakup | Categories |
Product | Dry Powder Inhalers, Metered Dosed Inhalers, Soft Mist Inhalers, Nebulizers (Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers) |
Type | Conventional Inhalers, Smart Inhalers |
Indication | Asthma, COPD |
End User | Hospitals, Clinics, Homecare Settings, Others |
Countries | Saudi Arabia, United Arab Emirates, Nigeria, South Africa, Others |
The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product |
|
Breakup by Type |
|
Breakup by Indication |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
Middle East and Africa Respiratory Inhalers Market Size
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The Middle East and Africa respiratory inhalers market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032 and is likely to reach a market value of USD 53.9 billion by 2032.
The rising burden of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) is fuelling the demand for the market.
One of the significant trends in the market is the rising investments in the development of sustainable respiratory inhalers. In April 2024, Mundipharma, in collaboration with Vectura announced plans to reformulate an established flutiform® pressurized metered-dose inhaler (pMDI) with the aim to reduce the product’s carbon footprint by incorporating an environmentally friendly propellant.
Based on the product, the market is segmented into dry powder inhalers, metered dosed inhalers, soft mist inhalers, and nebulizers. The nebulizer category is further bifurcated into jet nebulizers ultrasonic nebulizers, and mesh nebulizers.
By type, the market is divided into conventional inhalers and smart inhalers.
The market breakup by indication includes asthma and COPD.
End users of the market are hospitals, clinics, and homecare settings, among others.
The market segmentation by countries includes Saudi Arabia, the United Arab Emirates, Nigeria, and South Africa, among others.
The key players in the market are AstraZeneca Plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, Cipla Ltd, GSK Plc, Koninklijke Philips NV, OMRON Corp, Pari Respiratory Equipment, Inc., Teva Pharmaceutical Industries Ltd., and OPKO Health, Inc.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61 448 06 17 27
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63 287899028, +63 967 048 3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84865399124